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Abstract
Background:  Chronic fatigue syndrome (CFS) is characterized by profound fatigue, which
substantially interferes with daily activities, and a characteristic symptom complex. Patients use a
variety of prescribed and self-administered medications, vitamins, and supplements for relief of
their symptoms. The objective of this study was to describe utilization of medications and
supplements by persons with CFS and non-fatigued individuals representative of the general
population of Wichita, Kansas.
Methods: We used a random-digit dialing telephone survey to identify persons with CFS in the
general population of Wichita, Kansas. Subjects who on the basis of telephone interview met the
CFS case definition, and randomly selected non-fatigued controls, were invited for a clinic
evaluation that included self-reported use of medications and supplements. Sex-adjusted odds
ratios and 95% confidence interval were estimated to measure the association between CFS and
use of various drug categories.
Results: We clinically evaluated and classified 90 subjects as CFS during the study and also
collected clinical data on 63 who never described fatigue. Subjects with CFS reported using 316
different drugs compared to 157 reported by non-fatigued controls. CFS subjects were more likely
to use any drug category than controls (p = 0.0009). Pain relievers and vitamins/supplements were
the two most common agents listed by both groups. In addition CFS persons were more likely to
use pain relievers, hormones, antidepressants, benzodiazepines, gastro-intestinal, and central
nervous system medications (Sex-adjusted odds ratios range = 2.97 – 12.78).
Conclusion: Although the reasons for increased use of these agents were not elucidated, the data
indicated the CFS patients' need for symptom relief.
Background
Chronic fatigue syndrome (CFS) poses unique challenges
for health care providers and patients. Population-based
prevalence estimates range from 142 to 560 per 100,000
adults [1,2], which implies that the illness may affect at
least 800,000 adults in the United States http://eire.cen
sus.gov/popest/data/national/tables/asro/NA-EST2002-
ASRO-01.php. Their median duration of illness range
from 2 to 7 years [1,2], a quarter of them are unemployed
or receiving disability, and fewer than 20% have received
medical care for CFS [1-3]. However, CFS is an exclusion-
ary diagnosis based on a characteristic but non-specific
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symptom complex [4]. No diagnostic physical signs or
laboratory abnormalities and no single cause for CFS have
been identified, and the pathophysiology of the syn-
drome remains ill defined. Thus, treatment efforts are
directed at symptom relief, with the goal of the patient
regaining some level of pre-existing function and wellbe-
ing. Many health care providers prescribe pharmacologic
therapy to relieve fatigue and bothersome symptoms (e.g.,
pain or unrefreshing sleep). Individuals suffering from
CFS for prolonged periods may become frustrated with a
lack of acceptable recovery and self-medicate with over
the counter (OTC) medications and other supplements.
However, both prescribed and OTC medications can
cause untoward side effects, which may lead to new symp-
toms and exacerbate overall disability. Remarkably, no
population-based studies have documented use of medi-
cations by persons with CFS.
The objective of this study was to describe use of medica-
tions and supplements by persons with CFS and non-
fatigued individuals representative of the general popula-
tion of Wichita, Kansas. We wished to determine if per-
sons with CFS used more medications and supplements
than non-fatigued persons and to determine the nature of
medications/supplements used by the two groups. We
found a high level of medication/supplement use by both
groups and use of selective medications by individuals
with CFS.
Methods
The study adhered to human experimentation guidelines
of the U.S. Department of Health and Human Services
and of the Centers for Disease Control and Prevention
Institutional Review Board. All participants were volun-
teers who gave informed consent for the telephone inter-
view and clinical evaluation.
Study Design
The study has been described in detail [1,3,4]. Briefly, in
1997 we used random-digit-dialing phone interviews to
screen for fatigue among 56,146 adults 18 to 69 represent-
ing the Wichita population. We then conducted detailed
telephone interviews with 3,528 who reported fatigue
lasting for at least 1 month and 3,634 non-fatigued per-
sons. Fatigued individuals who, based on telephone inter-
view, met criteria for CFS (termed CFS-like) [4] and
randomly selected non-fatigued adults were further evalu-
ated clinically. A committee of physicians reviewed all the
clinical data and identified the fatigued subjects who
could be classified as CFS individuals. In 1998, 1999, and
2000, all previously interviewed subjects were re-con-
tacted by telephone and newly identified CFS-like subjects
and previously examined participants were evaluated clin-
ically. Thus, new CFS cases were identified throughout
the3-year follow-up period [1]. This analysis considered
information from individuals identified as CFS during
any year of the study.
Data Collection
During the clinical evaluation subjects underwent a stand-
ardized physical examination, were administered the
Diagnostic Interview Scheduling for DSM-IV psychiatric
disorders [4], and provided blood and urine samples for
routine clinical laboratory screening to fulfill evaluation
criteria recommended by the CFS case definition [4]. At
each clinic visit, subjects enumerated their medication
use, including prescription, OTC medications, and sup-
plements/ vitamins. Hereafter, these agents will be
referred to as "drugs" unless otherwise specified.
Statistics
We assessed differences in the prevalence of drug catego-
ries using the Fisher's exact or χ2 tests. Continuous varia-
bles were tested by the Wilcoxon rank-sum test or
Student's t-test. We fitted the logistic regression model to
estimate odds ratios and 95% confidence intervals to
measure the association between CFS and drug categories,
adjusting for sex. All tests were 2-sided and p-values were
considered significant if they did not exceed .05. We uti-
lized SAS version 8.1 (SAS Inc., Cary, NC) for all analyses.
Results
Description
Over the 4-year study period, 90 persons were classified as
CFS during at least one clinic evaluation. In this study, we
also considered longitudinal data for 63 clinically evalu-
ated individuals who did not report fatigue in the first year
of the study. Table 1 describes demographics in both
groups. There were no significant differences between CFS
and non-fatigued subjects with respect to age, race/ethnic-
ity, income, or education. However, subjects with CFS
were more likely than non-fatigued subjects to be female
(85.6% versus 57.1%, p = .0001). Median duration of CFS
was 6.9 years, the median age at onset was 36.5 years, and
79.3% reported a gradual onset.
Overall use of medications/supplements (drugs)
The CFS group reported use of 1174 medications identify-
ing 316 distinct drugs. There were 130 drugs reported only
once. The most frequently reported single drug was an
OTC acetaminophen preparation, being cited in 51
(4.3%) of the 1174 reports. Acetaminophen, however,
was a component of a total of 81 (6.8%) reported drugs.
Pain medications also included 82 (6.9%) reports of anti-
inflammatory agents including non-steroidal anti-inflam-
matory agents, with the most common being ibuprofen
(22 reports, 1.9%), COX-2 inhibitors and aspirin. Narcot-
ics and tramadol were reported in 16(1.3%) and 22
(1.8%) instances, respectively. There were an additionalHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/74
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25 (2.1%) reports of "OTC pain relievers" without further
identification.
The non-fatigued group reported 157 unique drugs
among 417 reports. There were 87 drugs reported only
once. Sixteen reports (3.8%) identified ibuprofen in any
form, but 38 (9.2%) reports included some type of non-
steroidal anti-inflammatory agents. Acetaminophen con-
taining agents totaled 11 (2.6%) and there was a single
report of narcotic analgesic use. Fifteen (3.6%) reports
listed unidentifiable "OTC pain relievers
Prevalence of drug categories in CFS and non-fatigued 
subjects
The subjects' reports of drugs were divided into 19 catego-
ries. These categories and examples of specific agents and
their drug families are described in Table 2.
Pain relieving drugs and supplements/vitamins were the
two drug categories most frequently reported by CFS and
non-fatigued subjects. However, CFS subjects used 7
categories of drugs more frequently than the non-fatigued
individuals. The 7 categories were: pain relievers, supple-
ments/vitamins, hormones, antidepressants, gastrointes-
tinal agents, central nervous system drugs, and
Table 1: Demographic characteristics of subjects with chronic fatigue syndrome (CFS) and non-fatigued subjects in Wichita, Kansas
Characteristic* CFS subjects (n = 90) Non-fatigued subjects (n = 63)
Age (mean years, SD) 44.4 (10.3) 43.3 (13.5)
Female (%) 85.6 57.1
Race/ethnicity (%)
White 90.0 93.7
African American 2.2 4.8
American Indian 5.6 0.0
Hispanic 1.1 0.0
Other 1.1 1.6
High School education (%) 62.2 74.6
Income ≥ $40,000 42.2 54.1
* No significant differences between CFS and non-fatigued subjects except for female sex (χ2 test, p < .0001)
Table 2: Categories of drugs, according to name of medication reported, used by subjects with CFS and non-fatigued subjects in 
Wichita, Kansas
Drug Category Name/type of medication
Pain reliever Tramadol hydrochloride, acetominophen, narcotics, NSAIDS, (including OTC preparations)
Supplements/vitamins Calcium, potassium, vitamins, dietary supplements
Hormones Estrogen, progesterone, levothyroxin, prednisone
Antidepressants Tricyclics, other (specific serotonin reuptake inhibitors, buspirone)
Allergy Oral antihistamines, nasal steroids
Gastrointestinal Antacids, H2 blockers, proton pump inhibitors
Antihypertensive Calcium channel blockers, acetylcholine esterase inhibitors
Cardiac Agents used in absence of history of hypertension (eg. beta-blockers)
Cold/sinus Antihistamines/decongestants, cough suppressants
Muscle relaxants Carisoprodol, cyclobenzaprin
Asthma Inhaled bronchodilators (BD), inhaled corticosteroids, oral BD
Diabetes Oral, insulin
Lipid-lowering agents HMG-CoA reductase inhibitors
Sleep Primary hypnotics (zolpidem tartrate, temazepam)
Diuretics Triamterene, hydrochlorthiazide, furosemide
Benzodiazepines Benzodiazepines
Antibiotics Antibacterials, antifungals, antivirals
Migraine Sumatriptan succianate, isometheptene Mucate/dichloralphenazone/acetaminophen
Central nervous system Gabapentin, chromium picolinateHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/74
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benzodiazepines (Table 3). CFS subjects reported a
median of 5 drug categories reported compared with 2
reported by non-fatigued persons (p value < 0.0001).
Association between CFS and drug categories adjusted for 
sex
Since women were much more common in the CFS group
and gender might account for the differences between
drug use patterns, we used logistic regression models to
measure the association between CFS illness and drug use,
adjusting for sex. Only significant results are reported
(Table 4). Female sex was only associated with use of sup-
plements/vitamins, and hormones. However, the associa-
tion of CFS with supplement/vitamins was no longer
significant after female sex was considered. To assess
whether the association of sex with drug categories was
the same among CFS and non-fatigued subjects, we fitted
additional logistic regression models including an interac-
tion term representing the joint effect of CFS and female
sex. No significant interaction terms were detected.
Drug use and duration of illness
We assessed whether duration of illness among CFS sub-
jects was associated with drug category use and found no
association with any drug category, except muscle relax-
ants. Subjects reporting muscle relaxant use had a shorter
duration of illness than those not reporting use (median
= 4.1 and 7.8 years, respectively, p = .0402).
Table 3: Prevalence of drug category use among CFS and non-fatigued subjects in Wichita, Kansas
Drug Category CFS subjects (n = 90) Non-fatigued subjects (n = 63) p-value
Pain reliever 87.8 47.6 <.0001
Supplements/Vitamins 62.2 42.9 .0180
Hormones 52.2 20.6 <.0001
A l l e r g y 4 4 . 43 0 . 2. 0 7 4 0
Antidepressants 41.1 11.1 <.0001
Gastrointestinal 32.2 14.3 .0115
Cold/sinus 30.0 22.2 .2851
Central nervous system 24.4 4.8 .0012
Antihypertensive 21.1 14.3 .2826
Antibiotics 16.7 14.3 .6902
Diuretics 13.3 7.9 .2958
Lipid-lowering 12.2 9.5 .6012
Muscle relaxants 12.2 4.8 .1152
Asthma 12.2 6.4 .2292
Benzodiazepines 11.1 1.6 .0273
Sleep 7.8 3.2 .3087
Cardiac 6.7 7.9 .7613
Migraine 4.4 6.4 .7178
Diabetes 4.4 1.6 .6492
Any category 97.8 82.5 0.0009
Table 4: Associations between drug categories and CFS status and sex in CFS subjects using drugs in Wichita, Kansas
Drug category CFS versus Non-fatigued OR*, (95% CI) Female versus Male OR (95% CI)
Pain relievers 6.51 (2.85–14.88) 2.26 (0.97–5.28)
Supplements/vitamins 1.68 (0.84–3.38) 2.84 (1.29–6.32)
Hormones 2.97 (1.35–6.51) 9.51 (2.71–33.34)
Antidepressants 4.62 (1.85–11.53) 2.38 (0.82–6.95)
Gastrointestinal 2.67 (1.12–6.36) 1.28 (0.49–3.38)
Central nervous system 6.85 (1.85–25.30) 0.83 (0.26–2.62)
Benzodiazepines 12.78 (1.39–108.34) 0.28 (0.07–1.15)
*OR, odds ratio; CI, confidence interval; † Odds ratios were adjusted for other variables in the table since they were all included in the logistic 
regression modelHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/74
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Drug use and change to non-fatigued state
Of the 90 subjects ever classified with CFS, 65 underwent
at least one subsequent clinical evaluation [5]. Of those,
50 reported persistent fatigue at follow-up but 15 reported
they were no longer fatigued. We questioned whether
drug use differed between the two groups. The median dif-
ference between the number of medications was 1. The
only drug category associated with persistent CFS was gas-
trointestinal medications (60% among subjects who ever
changed to a non-fatigued state versus 28% of subjects
who remained in the CFS group, P = 0.0230).
Discussion
This study clearly documented that, within the general
population, persons with CFS were significantly more
likely to use medications than non-fatigued individuals.
However, CFS and control subjects used similar types of
drugs.
We are not aware of comparable population-based reports
of medication use by people with CFS or with fatiguing ill-
nesses. CFS-associated reports are primarily medication
trials and were recently reviewed by Whiting et al [6]. It is
likely not a coincidence that of the few population reports
regarding medication use in general, most describe use of
pain and sleep medication since problems with pain and
sleep are commonly reported to medical practitioners.
However, most medications identified in this study may
not reflect treatment of fatigue or other symptoms of CFS.
The exceptions are medications for pain (ranked as
number 1 in this study) that would influence arthralgia,
myalgia, and headaches; medications for post-nasal drip
associated sore throat, which might include allergy medi-
cations (#5); muscle relaxants (#10), which could influ-
ence myalgia; sleep medications (#14), which obviously
would be used for sleep disturbances; benzodiazepines
(#16), which could influence sleep disturbances, muscle
aches, headaches, and possibly exertion-related symp-
toms; and CNS medications (#19), which could influence
headaches, sleep disturbances, and cognitive problems
associated with CFS. The drugs that were used equally by
the two groups could simply reflect treatment of age-
related illnesses. We are left with the unanswered question
of why CFS subjects use more supplements/vitamins, hor-
mones, antidepressants, and gastrointestinal drugs than
do non-fatigued subjects or why they reported use of any
drug only on one occasion.
This question highlights a major limitation of the study in
regard to assignment of medication use, because we did
not obtain the subject's perception concerning the prob-
lem(s) that prompted medication use. In particular, no
specific questions addressed methods of combating
fatigue per se. In addition, we did not address non-phar-
macologic approaches to symptom relief, such as acu-
puncture. Since CFS patient perception of the adequacy
and efficacy of medical care also affects therapy, absence
of their perceptions may also influence our findings [7].
Comparable data for medication use in general in the
United States are difficult to find. Medication use in Nor-
way from 1988 to 1989 [8] provides an interesting point
of comparison. In our data set, pain medications were the
most frequently utilized drugs, whereas in the Norwegian
study they were the second most commonly used drugs by
both men and women. An antibiotic was the medication
most commonly used by Norwegian men and anxiolytics
were the most frequently used medication in women.
These differences in ranking of drug use may have little
meaning because in both studies, the lists of the 10 most
frequently used agents contained the same medications.
Identification of medication use patterns may also rely on
identification of the symptoms or problems under ther-
apy. As reported by Mäntyselka et al. [9], use of pain med-
ications for non-acute pain is common. Another report
from a study of general practice use of non-steroidal anti-
inflammatory drugs (NSAIDS) in the United Kingdom
found prescribing rates ranging from 220 to over 700 per
1000 patient visits [10]. In both of these reports, the
patients sought care for the primary complaint of pain.
Even though pain was a common complaint, but not nec-
essarily the primary problem in the current study, almost
90% of CFS subjects used pain medication. It is not clear
why CFS subjects used more acetaminophen and central
nervous system acting drugs than did the non-fatigued
subjects. Medication use for pain is complex, as demon-
strated by Mäntyselka et al [9], in that use of sedatives and
anxiolytics accompanied the use of analgesics; use of these
categories of drugs was also seen in our study.
Vitamin and dietary supplements constituted the second
most frequently identified category of drugs used by CFS
and non-fatigued subjects. These agents may be obtained
directly by the individual or prescribed by a health care
provider. As reviewed by Messerer et al. [11], supplement
use in the United States population-at large ranged from
21% to 55%. In a previous analysis of vitamin/supple-
ment use by 30 CFS subjects attending a referral clinic,
89% of patient subjects versus 40% of control subjects
reported use of these agents [12].
Use of medications in general populations [13] and in the
pain and supplement studies described above supports
greater use by women. We determined similar overall dif-
ferences between men and women in our study, but CFS-
and sex-influenced odds ratios of medication use were
independent. In other words, medication use by women
is more common than by men and CFS is more commonPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/74
Page 6 of 6
(page number not for citation purposes)
in women, but medication use in CFS is not dependent on
the subject being female.
Conclusion
These observations support the concept that the morbid-
ity associated with CFS leads patients to seek relief of ill-
ness by the use of prescription and non-prescription
medications and supplements. Changes in fatigue status
did not correlate with changes in use of common medica-
tions, however. The pursuit of symptom relief in the
absence of supportive clinical trials is a strong indication
of the desire of CFS patients to improve or to alleviate
their symptoms and should serve as impetus for further
research into the origins, consequences, and treatment of
fatiguing illnesses.
Examination of the processes that lead to more medica-
tion use in general by individuals with fatigue is of high
priority in terms of public health in general.
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